Evidence map›Paper›PMID 36009117›Full record

ArticleBrain sciences2022

Retrospective Multicenter Study on Outcome Measurement for Dyskinesia Improvement in Parkinson's Disease Patients with Pallidal and Subthalamic Nucleus Deep Brain Stimulation.

Fangang Meng, Shanshan Cen, Zhiqiang Yi, Weiguo Li, Guoen Cai, Feng Wang, Stephan S Quintin, Grace E Hey, Jairo S Hernandez, Chunlei Han and 8 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Brain sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 85% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 9 institutions in 2 countries.

Fangang MengBeijing Neurosurgical Institute, Capital Medical University, Beijing 100070, China.
Shanshan CenDepartment of Neurology, Xuanwu Hospital, Beijing 100053, China.
Zhiqiang YiDepartment of Neurosurgery, Peking University First Hospital, Beijing 100034, China.
Weiguo LiDepartment of Neurosurgery, QiLu Hospital of Shandong University, Jinan 250012, China.
Guoen CaiDepartment of Neurology, Fujian Medical University Union Hospital, Fuzhou 350001, China.
Feng WangDepartment of Neurosurgery, General Hospital of Ningxia Medical University, Yinchuan 750004, China.
Stephan S QuintinDepartment of Neurology, Fixel Center for Neurological Diseases, Program in Movement Disorders and Neurorestoration, University of Florida, Gainesville, FL 32607, USA.ORCID 0000-0002-5880-8470
Grace E HeyDepartment of Neurology, Fixel Center for Neurological Diseases, Program in Movement Disorders and Neurorestoration, University of Florida, Gainesville, FL 32607, USA.
Jairo S HernandezDepartment of Neurology, Fixel Center for Neurological Diseases, Program in Movement Disorders and Neurorestoration, University of Florida, Gainesville, FL 32607, USA.
Chunlei HanDepartment of Functional Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China.
Shiying FanDepartment of Functional Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China.
Yuan GaoBeijing Neurosurgical Institute, Capital Medical University, Beijing 100070, China.
Zimu SongDepartments of Neurosurgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310058, China.
Junfei YiDepartment of Neurosurgery, QiLu Hospital of Shandong University, Jinan 250012, China.
Kailiang WangBeijing Neurosurgical Institute, Capital Medical University, Beijing 100070, China.ORCID 0000-0003-1680-6124
Liangwen ZhangDepartment of Neurosurgery, Shandong Provincial Hospital Affiliated to Shandong University, Jinan 250021, China.
Adolfo Ramirez-ZamoraDepartment of Neurology, Fixel Center for Neurological Diseases, Program in Movement Disorders and Neurorestoration, University of Florida, Gainesville, FL 32607, USA.
Jianguo ZhangDepartment of Functional Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China.
Capital Medical University · CNUniversity of Florida · USQilu Hospital of Shandong University · CNBeijing Xuanwu Traditional Chinese Medicine Hospital · CNFirst Affiliated Hospital Zhejiang University · CNFujian Medical University · CNNingxia Medical University · CNPeking University · CNShandong University · CN

Funding

Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding Support XMLX201833Joint Funds for the Innovation of Science and Technology, Fujian Province 2017Y9010Key Research and Development Program of Ningxia 2018BFG02007National Natural Science Foundation of China 81971070
6 · The paper itself

Abstract

Deep brain stimulation (DBS) is an effective treatment for dyskinesia in patients with Parkinson’s disease (PD), among which the therapeutic targets commonly used include the subthalamic nucleus (STN) and the globus pallidus internus (GPi). Levodopa-induced dyskinesia (LID) is one of the common motor complications arising in PD patients on chronic treatment with levodopa. In this article, we retrospectively evaluated the outcomes of LID with the Unified Dyskinesia Rating Scale (UDysRS) in patients who underwent DBS in multiple centers with a GPi or an STN target. Meanwhile, the Med off MDS-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS-Ⅲ) and the levodopa equivalent daily dose (LEDD) were also observed as secondary indicators. PD patients with a GPi target showed a more significant improvement in the UDysRS compared with an STN target (92.9 ± 16.7% vs. 66.0 ± 33.6%, p < 0.0001). Both the GPi and the STN showed similar improvement in Med off UPDRS-III scores (49.8 ± 22.6% vs. 52.3 ± 29.5%, p = 0.5458). However, the LEDD was obviously reduced with the STN target compared with the GPi target (44.6 ± 28.1% vs. 12.2 ± 45.8%, p = 0.006).

Indexed as

deep brain stimulationlevodopa equivalent daily doselevodopa-induced dyskinesiaParkinson’s diseaseUnified Dyskinesia Rating Scale

Identifiers

PMID36009117
PMCPMC9405623
OpenAlexW4292466648

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.